Diabetes Clinical Trials in Boston

Showing 441-460 of 534 trials

A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus

NCT01421355

Specific Aim: To establish the feasibility of studying the change in endothelial function caused by induced moderate hyperbilirubinemia in type 1 diabetes. Atazanavir, a drug that inhibits bilirubin conjugation, will be used to induce moderate hyperbilirubinemia. Endothelial function will be measured before and after atazanavir therapy. In addition, plasma markers of antioxidant capacity and oxidant stress will be measured as proof-of-concept that induced moderate hyperbilirubinemia has favorable effects on oxidative stress in type 1 diabetes.

Type 1 Diabetes Mellitus

Brigham and Women's Hospital15 participantsStarted May 2012

Boston, Massachusetts, United States

COMPLETEDPhase 4< 1 mile

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

NCT01107886

The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications

Type 2 Diabetes Mellitus

AstraZeneca18,206 participantsStarted May 2010

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tempe, Arizona, United States +533 more locations

A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Diabetes Trials in Other Cities

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Flavanol-Rich Cocoa and Cerebral Blood Flow

Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study

Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk

A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

Markers and Mechanisms of Vascular Disease in Type II Diabetes

Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Dapagliflozin DPPIV Inhibitor add-on Study

Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Other Conditions in Boston